NR4A1 and cancer: Type I, more common (~ 70 to 80%) and of a lower risk, consists of estrogen-driven endometrioid, low grade, diploid, hormone receptor-positive tumors, whereas type II comprises less common (20–30%), more aggressive, nonestrogen-driven cancers of a non-endometrioid histology, high-grade, aneuploid, poorly differentiated, hormone receptor negative and associated with a higher risk of metastasis and a poor prognosis3–5.